Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba, discusses how comorbidities affect treatment and options for patients with multiple sclerosis (MS).
Transcript
How does the presence of comorbidities affect treatments and outcomes for MS?
Well, in terms of outcomes, the effects of comorbidities really affect the entire trajectory of multiple sclerosis. So if we go back to when people first have symptoms of MS, and they're working through that diagnostic process, people who already have another health condition at the time their symptoms start have a longer time to diagnosis. So greater diagnostic delay. People with multiple comorbid conditions at the time of diagnosis tend to have more severe disability at the time of diagnosis, and then disability progression appears to be faster over the course of the illness if you have conditions such as depression, or cardiovascular comorbidities like hypertension, diabetes, hyperlipidemia. Relapse rates appear to be higher if you have multiple comorbidities, so at least 3 or more, or if you have hyperlipidemia, or anxiety disorders. And then things that are more patient centered in terms of their mental health related quality of life are produced in the presence of comorbid conditions. And of the ones that we've talked about so far depression and anxiety disorder seem to have the most adverse impact on quality of life. We need to recognize that many of the medications that we're using as disease-modifying therapies now, for example, may have contraindications in the presence of some comorbid conditions or medications used to treat those conditions. Fingolimod is an example, or siponimod; if you have ischemic heart disease, you're taking beta blockers, calcium channel blockers—contraindications. So we need to think about those kinds of things in the choice of medications. But we also need to recognize that people may have a harder time staying on their disease-modifying therapies, if they have multiple other conditions that they're already dealing with for reasons we haven't fully explored, but it's a big burden to taking multiple medications and side effects from one medication may affect you know, other conditions. And so it is important for us to think about all those issues when talking to the individual with MS about what medication is going to be best suited for them.
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More